Cargando…

Optimizing Patient Management and Adherence for Children Receiving Growth Hormone

Poor adherence with growth hormone (GH) therapy has been associated with worse clinical outcomes, which in children relates specifically to their linear growth and loss of quality of life. The “360° GH in Europe” meeting, held in Lisbon, Portugal, in June 2016 and funded by Merck KGaA (Germany), exa...

Descripción completa

Detalles Bibliográficos
Autores principales: Acerini, Carlo L., Wac, Katarzyna, Bang, Peter, Lehwalder, Dagmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701910/
https://www.ncbi.nlm.nih.gov/pubmed/29209274
http://dx.doi.org/10.3389/fendo.2017.00313
_version_ 1783281415644774400
author Acerini, Carlo L.
Wac, Katarzyna
Bang, Peter
Lehwalder, Dagmar
author_facet Acerini, Carlo L.
Wac, Katarzyna
Bang, Peter
Lehwalder, Dagmar
author_sort Acerini, Carlo L.
collection PubMed
description Poor adherence with growth hormone (GH) therapy has been associated with worse clinical outcomes, which in children relates specifically to their linear growth and loss of quality of life. The “360° GH in Europe” meeting, held in Lisbon, Portugal, in June 2016 and funded by Merck KGaA (Germany), examined many aspects of GH diseases. The three sessions, entitled “Short Stature Diagnosis and Referral,” “Optimizing Patient Management,” and “Managing Transition,” each benefited from three guest speaker presentations, followed by an open discussion and are reported as a manuscript, authored by the speakers. Reported here is a summary of the proceedings of the second session, which reviewed the determinants of GH therapy response, factors affecting GH therapy adherence and the development of innovative technologies to improve GH treatment in children. Response to GH therapy varies widely, particularly in regard to the underlying diagnosis, although there is little consensus on the definition of a poor response. If the growth response is seen to be less than expected, the possible reasons should be discussed with patients and their parents, including compliance with the therapy regimen. Understanding and addressing the multiple factors that influence adherence, in order to optimize GH therapy, requires a multi-disciplinary approach. Because therapy continues over many years, various healthcare professionals will be involved at different periods of the patient’s journey. The role of the injection device for GH therapy, frequent monitoring of response, and patient support are all important for maintaining adherence. New injection devices are incorporating electronic technologies for automated monitoring and recording of clinically relevant information on injections. Study results are indicating that such devices can at least maintain GH adherence; however, acceptance of novel devices needs to be assessed and there remains an on-going need for innovations.
format Online
Article
Text
id pubmed-5701910
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-57019102017-12-05 Optimizing Patient Management and Adherence for Children Receiving Growth Hormone Acerini, Carlo L. Wac, Katarzyna Bang, Peter Lehwalder, Dagmar Front Endocrinol (Lausanne) Endocrinology Poor adherence with growth hormone (GH) therapy has been associated with worse clinical outcomes, which in children relates specifically to their linear growth and loss of quality of life. The “360° GH in Europe” meeting, held in Lisbon, Portugal, in June 2016 and funded by Merck KGaA (Germany), examined many aspects of GH diseases. The three sessions, entitled “Short Stature Diagnosis and Referral,” “Optimizing Patient Management,” and “Managing Transition,” each benefited from three guest speaker presentations, followed by an open discussion and are reported as a manuscript, authored by the speakers. Reported here is a summary of the proceedings of the second session, which reviewed the determinants of GH therapy response, factors affecting GH therapy adherence and the development of innovative technologies to improve GH treatment in children. Response to GH therapy varies widely, particularly in regard to the underlying diagnosis, although there is little consensus on the definition of a poor response. If the growth response is seen to be less than expected, the possible reasons should be discussed with patients and their parents, including compliance with the therapy regimen. Understanding and addressing the multiple factors that influence adherence, in order to optimize GH therapy, requires a multi-disciplinary approach. Because therapy continues over many years, various healthcare professionals will be involved at different periods of the patient’s journey. The role of the injection device for GH therapy, frequent monitoring of response, and patient support are all important for maintaining adherence. New injection devices are incorporating electronic technologies for automated monitoring and recording of clinically relevant information on injections. Study results are indicating that such devices can at least maintain GH adherence; however, acceptance of novel devices needs to be assessed and there remains an on-going need for innovations. Frontiers Media S.A. 2017-11-20 /pmc/articles/PMC5701910/ /pubmed/29209274 http://dx.doi.org/10.3389/fendo.2017.00313 Text en Copyright © 2017 Acerini, Wac, Bang and Lehwalder. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Acerini, Carlo L.
Wac, Katarzyna
Bang, Peter
Lehwalder, Dagmar
Optimizing Patient Management and Adherence for Children Receiving Growth Hormone
title Optimizing Patient Management and Adherence for Children Receiving Growth Hormone
title_full Optimizing Patient Management and Adherence for Children Receiving Growth Hormone
title_fullStr Optimizing Patient Management and Adherence for Children Receiving Growth Hormone
title_full_unstemmed Optimizing Patient Management and Adherence for Children Receiving Growth Hormone
title_short Optimizing Patient Management and Adherence for Children Receiving Growth Hormone
title_sort optimizing patient management and adherence for children receiving growth hormone
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701910/
https://www.ncbi.nlm.nih.gov/pubmed/29209274
http://dx.doi.org/10.3389/fendo.2017.00313
work_keys_str_mv AT acerinicarlol optimizingpatientmanagementandadherenceforchildrenreceivinggrowthhormone
AT wackatarzyna optimizingpatientmanagementandadherenceforchildrenreceivinggrowthhormone
AT bangpeter optimizingpatientmanagementandadherenceforchildrenreceivinggrowthhormone
AT lehwalderdagmar optimizingpatientmanagementandadherenceforchildrenreceivinggrowthhormone